Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity.

By D. Vaughn, S. Green, S. Kalayanarooj, B. Innis, S. Nimmannitya, S. Suntayakorn, T. Endy, B. Raengsakulrach, A. Rothman, F. Ennis and 1 more. Journal of Infectious Diseases, 2000

1,708 citations recorded by the source corpus.

Subfields: Infectious Diseases, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/db8caa81e2f8a85af2a85c91695fb60a2fd40fbc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

1. Yong‐Zhen Zhang
2. Edward C. Holmes
3. E. Harris
4. J. Kyle

In Public Health, Environmental and Occupational Health

1. Yong‐Zhen Zhang
2. Edward C. Holmes
3. E. Harris
4. Thomas W. Scott
5. Simon Iain Hay
6. J. Kyle
7. A. McMichael

Citations in the corpus

• Refining the Global Spatial Limits of Dengue Virus Transmission by Evidence-Based Consensus (2012, methodology): “Medium accuracy methods including IgM- and IgG- based ELISA and Hemagglutination Inhibition (HI) assay approaches scored 2 because their calibration is sensitive to background immune responses [20], antibody response is variable over the course of an infection [21] and the test can cross-react with ”
• Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms (2011, background): “First, dengue haemorrhagic fever can occur, albeit at a lower frequency, in primary dengue virus infection in older children and adults, and this indicates that antibody-dependent enhancement is not required for the development of plasma leakag”
• Dengue Virus Pathogenesis: an Integrated View (2009, background): “ADE could result in infection of a higher number of target cells, which could lead to the high viral load observed in many studies (132, 221, 245, 251, 258, 259).”
• Global spread and persistence of dengue. (2008, background): “DENV2 and DENV4 have been associated with increased disease severity as a secondary infection, whereas DENV1 and DENV3 seem to cause more severe disease in primary infection than do the other two serotypes (9, 62, 96, 145).”
• Dengue: a continuing global threat (2010, background): “One advantage of this assay is the ability to determine viral titre early in dengue illness, which is believed to be an important predictor of disease severity 102 .”
• High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. (2002, methodology): “Most DHF cases occur after sequential heterotypic DV infections (secondary infection) [3], and circulating DV levels early in illness correlate with increasing dengue disease severity [4, 5].”
• Prospects for a dengue virus vaccine (2007, background): “Viraemia is generally 10–100-fold greater in DHF and DSS than in D”
• Dengue and severe dengue (2025, neutral): “Inhibiting DENV infection can either be through discovering compounds that either directly bind viral proteins, also referred to as direct-acting antiviral (DAA) compound, or inhibit host factors required for DENV infection (273, 274).”
• The Evolution and Emergence of RNA Viruses (2009, background): “In addition, an increase in the level of viraemia is normally expected to lead to an increase in disease severity in humans, as there is a strong association between viral load and morbidity (Vaughn et al. 2000).”
• Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever (2003, background): “Patients develop a high fever for 2–7 d, which corresponds to a period of high viremi”